From the Open Medicine Foundation:
In the spirit of collaboration, we are forwarding this invitation to ME/CFS patients and organizations to forward to their members for a ME/CFS clinical trial ,” The Synergy Trial,” by K-Pax Pharmaceuticals. They are recruiting until August 1, 2014.
Please see details of the trial, testing sites and contact information below. We are simply passing on this information and are not involved in this particular trial. All contact will be with K-Pax; see contact information below.
If you’re looking to take part in testing an innovative new ME/CFS treatment, one that has already demonstrated positive preliminary results according to K-Pax, then please take a close look at the Youtube below regarding “The Synergy Trial” – a combination of low dose methylphenidate (generic ritalin) plus a highly potent combination of mitochondrial support nutrients.
According to K-Pax, when this combination of treatments (low dose methylphenidate plus the ME/CFS Nutrient Formula) was recently provided to ME/CFS patients as innovative therapy, many patients reported rapid and sustained reductions in fatigue as well as improvement in concentration (brain fog). The Synergy Trial represents the next phase of study for this intervention. It is believed that the mitochondrial nutrients help the methylphenidate work better and be better tolerated.
The Synergy Trial has already enrolled 90 patients. 40 additional patients are now needed by August 1st!
The 4 sites are located at the following clinics:
Palo Alto, CA (Jose Montoya, MD)
Salt Lake City (Lucinda Bateman, MD)
New York City (Sue Levine, MD)
Ft. Lauderdale (Nancy Klimas, MD)
This is a 3-month trial and there are a total of 4 in-person visits plus 2-3 phone calls. Remuneration is provided at $50 per visit (after the screening visit) to cover expenses. A free 3-month supply of the ME/CFS Nutrient Formula will also be provided to all who complete the trial.
K-PAX Pharmaceuticals, the study’s sponsor, has recently posted a webcast on YouTube that covers all the details of the study including its mechanism of action and the early data that has been collected.
to view the webcast:
For more information about the K-Pax trial you may call “The Hope Line”
1-855-318-HOPE (4673); K-PAX Research Coordinator, D.email@example.com,